Immunomedics regulatory update

IMMU received notice of allowance from the U.S. Patent and Trademark Office for a patent covering new methods of targeting diagnostic agents directly to the site of an infection. IMMU said the patent covers technology that enables targeting of multiple sites on a pathogen, as opposed to a single site.

IMMU also was issued Australian Patent No. AU-B-34249 covering the combination of cytokines, particularly blood cell growth factors such as interleukins, with radiolabeled antibodies to treat cancers, autoimmune diseases, and as anti-rejection agents for tissue and organ transplantation. ...